Dec. 13 at 5:01 PM
$VKTX It still makes no sense to me why BL de-prioritized VK2809's clinical development. Sure, MASH is a very competitive space, but other than
$MDGL 's Rezdiffra, no other drugs are currently on market now. And is VK2809 really inferior to Rezdiffra which is of the same class? If you worry about Biopsy requirement to confirm fibrosis improvement in the readout, FDA now has revised protocol on that. Although biopsy is still a must, only one pathologist is now required for fibrosis evaluation, and you can now use the newly FDA-qualified PathAI tools to interpret histology by NITs which largely reduces bias and turnaround time (same as what
$ALT did).
$MDGL has its entire franchise built on Rezdiffra, and has a new PT at
$670/share (equivalent to 15B).
It's insane to totally ditch VK2809 imho.
